Fmoc-Val-Cit-PAB

Fmoc-Val-Cit-PAB, also known as 9-fluorenylmethyloxycarbonyl-Valine-Citrulline-p-aminobenzyloxycarbonyl, is a specialized peptide linker widely utilized in the synthesis of antibody-drug conjugates (ADCs) and other targeted therapeutic agents. This compound features a cleavable dipeptide sequence, Valine-Citrulline, which is sensitive to specific intracellular proteases, and is coupled with a p-aminobenzyloxycarbonyl (PAB) self-immolative spacer. The Fmoc group serves as a protective moiety during solid-phase peptide synthesis, ensuring stability and facilitating the selective assembly of complex molecules. Its unique structural attributes make it an indispensable tool in modern drug discovery, particularly in the development of molecules that require precise, controlled release mechanisms within biological systems.

Antibody-Drug Conjugate Development: Fmoc-Val-Cit-PAB is a cornerstone in the design and synthesis of ADCs, where it functions as a cleavable linker between a monoclonal antibody and a cytotoxic payload. The Val-Cit dipeptide is specifically recognized and cleaved by cathepsin B and related proteases, which are abundant in the lysosomal compartments of target cells. Upon internalization of the ADC by the target cell, enzymatic cleavage at the Val-Cit site triggers the release of the active drug, facilitated by the self-immolative PAB spacer. This mechanism enables selective drug release within the tumor microenvironment, thereby improving the therapeutic index and minimizing off-target effects. The use of Fmoc protection during synthesis allows for high-fidelity assembly of the linker-payload construct, ensuring functional integrity throughout the conjugation process.

Targeted Prodrug Strategies: In addition to ADCs, Fmoc-Val-Cit-PAB finds application in the engineering of targeted prodrugs. By linking a therapeutic agent to the Val-Cit-PAB motif, researchers create prodrugs that remain inactive in systemic circulation but are selectively activated by proteolytic cleavage in disease-specific cellular environments. The self-immolative PAB unit ensures rapid and complete release of the parent drug upon enzymatic activation, enhancing bioavailability at the intended site of action. This approach addresses challenges associated with systemic toxicity and poor pharmacokinetics, offering a modular solution for the controlled delivery of a wide range of small-molecule therapeutics.

Peptide-Drug Conjugate Synthesis: The compound is also employed in the preparation of peptide-drug conjugates (PDCs), where it serves as a versatile linker for attaching cytotoxic or imaging agents to targeting peptides. The Fmoc group allows for stepwise solid-phase synthesis, enabling precise incorporation of the Val-Cit-PAB linker into complex peptide chains. Once the targeting peptide binds to its cellular receptor and is internalized, intracellular proteases cleave the linker, resulting in efficient release of the conjugated agent. This strategy enhances the specificity and efficacy of PDCs, making Fmoc-Val-Cit-PAB a valuable asset in the development of next-generation targeted therapeutics.

Enzyme-Responsive Drug Delivery Systems: The unique enzyme-cleavable nature of Val-Cit-PAB linkers has been harnessed to create advanced drug delivery systems that respond to specific proteolytic environments. Researchers design nanoparticles, liposomes, or polymeric carriers incorporating the Val-Cit-PAB motif to achieve enzyme-triggered release of encapsulated drugs. This approach is particularly advantageous in targeting tumors or inflamed tissues, where upregulated protease activity can be exploited for site-specific drug activation. The modularity of Fmoc-Val-Cit-PAB enables its integration into a variety of carrier platforms, supporting the development of smart, responsive delivery vehicles.

Chemical Biology and Protease Activity Probes: Beyond its use in therapeutic delivery, Fmoc-Val-Cit-PAB is employed in chemical biology research as a component of protease-sensitive probes. By attaching reporter molecules or fluorophores to the PAB group, scientists can create substrates that emit a detectable signal upon cleavage by target proteases. These probes are instrumental in studying protease activity in vitro and in cell-based assays, facilitating the discovery of novel inhibitors and providing insights into disease-associated proteolytic pathways. The combination of Fmoc protection, enzyme-sensitive dipeptide, and self-immolative spacer makes Fmoc-Val-Cit-PAB an essential building block for the rational design of functional chemical tools in protease research.

1. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling

2. The effect of B-type allatostatin neuropeptides on crosstalk between the insect immune response and cold tolerance

3. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I

4. Multifunctional peptide-oligonucleotide conjugate promoted sensitive electrochemical biosensing of cardiac troponin I

5. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides